CNS Discovery Xchange - Boston - 2026

Target Discovery

Navigating pathway redundancy to unlock novel CNS targets

09:05 – 10:05
- Target Discovery
Daniel Klamer, Vice President (Business Development & Scientific Strategy) - Anavex Life Sciences
Target Discovery

Sponsor Led Roundtable: Bridging omics discoveries with functional target validation in the brain

11:20 – 12:20
- Target Discovery
Target Discovery

Poster Presentation: Addressing disease heterogeneity in neurodegenerative and psychiatric target discovery

15:05 – 15:35
- Target Discovery
Target Discovery

Innovating approaches to measure target engagement in the CNS

15:45 – 16:45
- Target Discovery
Registration

08:00 – 08:30
- Target Discovery
- Disease Models
- Novel Modalities
- Blood Brain Barrier
Opening Address & Keynote Presentation:

08:30 – 09:30
- Target Discovery
- Disease Models
- Novel Modalities
- Blood Brain Barrier
1-2-1 Meetings / Networking Break

10:40 – 11:10
- Target Discovery
- Disease Models
- Novel Modalities
- Blood Brain Barrier
1-2-1 Meetings / Networking Break

10:10 – 10:40
- Target Discovery
- Disease Models
- Novel Modalities
- Blood Brain Barrier
Morning Refreshments

11:10 – 11:20
- Target Discovery
- Disease Models
- Novel Modalities
- Blood Brain Barrier
Networking Lunch

12:20 – 13:20
- Target Discovery
- Disease Models
- Novel Modalities
- Blood Brain Barrier
Spotlight Presentation:

13:25 – 13:55
- Target Discovery
- Disease Models
- Novel Modalities
- Blood Brain Barrier
1-2-1 Meetings / Networking Break

14:30 – 15:00
- Target Discovery
- Disease Models
- Novel Modalities
- Blood Brain Barrier
1-2-1 Meetings / Networking Break

14:00 – 14:30
- Target Discovery
- Disease Models
- Novel Modalities
- Blood Brain Barrier
Evening Drinks Reception

16:45 – 17:45
- Target Discovery
- Disease Models
- Novel Modalities
- Blood Brain Barrier
Afternoon Refreshments

15:35 – 15:45
- Target Discovery
- Disease Models
- Novel Modalities
- Blood Brain Barrier
Disease Models

Overcoming the translational gap between preclinical CNS models and human outcomes

09:05 – 10:05
- Disease Models
Lorelai Stoica, Lorelai Stoica, Executive Director, Nonclinical Research, Ultragenyx - Ultragenyx
Disease Models

Sponsor Led Roundtable: Capturing human neural circuitry complexity in disease modeling

11:20 – 12:20
- Disease Models
Disease Models

Poster Presentation: Tackling species differences to improve neurobiological model accuracy

15:05 – 15:35
- Disease Models
Disease Models

Closing the biomarker gap for reliable CNS target engagement readouts

15:45 – 16:45
- Disease Models
Novel Modalities

Balancing innovation in new modalities with neurotoxicity and safety concerns

09:05 – 10:05
- Novel Modalities
Shyam Ramachandran, Executive Director of Genomic Medicines for Neurological and Immunological Diseases - Sanofi
Novel Modalities

Sponsor Led Roundtable: Pursuing precision medicine in heterogeneous CNS patient populations

11:20 – 12:20
- Novel Modalities
Novel Modalities

Poster Presentation: Integrating novel modalities with existing CNS treatment paradigms

15:05 – 15:35
- Novel Modalities
Novel Modalities

Applying AI-driven chemistry to accelerate novel modality design

15:45 – 16:45
- Novel Modalities
Blood Brain Barrier

Breaking through the blood–brain barrier to enable effective CNS therapies [Topic TBC]

09:05 – 10:05
- Blood Brain Barrier
Larry Brown, Executive Vice President & Chief Scientific Officer - Noveome
Blood Brain Barrier

Sponsor Led Roundtable: Optimizing CNS penetration while minimizing systemic toxicity

11:20 – 12:20
- Blood Brain Barrier
Blood Brain Barrier

Poster Presentation: Evaluating the translational impact of nanotechnology and advanced carriers

15:05 – 15:35
- Blood Brain Barrier
Blood Brain Barrier

Developing robust methods to track drug distribution and target engagement beyond the BBB [Topic TBC]

15:45 – 16:45
- Blood Brain Barrier
Susan Rosenbaum, Founder, Chairman & CEO - Lauren Sciences